VTx-001 – ALS treatment

• VTx-001 publication – Gomes-Duarte et al (2025) Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab

• VTx-001 publication – Gomes-Duarte et al (2025) AAV-delivered anti-PC-OxPL antibody fragments: a novel therapeutic approach to target ALS

• Target ALS poster – Gomes-Duarte et al (2025) AAV-delivered anti-PC-OxPL antibody fragments: a novel therapeutic approach to target ALS

VTx-002 – ALS treatment

• MNDA poster - Sogorb et al. (2022), VecTabs® and advanced human in-vitro models: Targeting TDP-43 aggregates and oxidized phosphocholines in amyotrophic lateral sclerosis

• ASGCT poster – Miranda et al (2025) AAV-mediated delivery of an intrabody targeting TDP-43 for Amyotrophic Lateral Sclerosis therapy

VTx-003 - HD treatment

• DHDRN presentation - Konstantinova (2023), Precision targeted therapies for neurodegenerative diseases

• HDF poster - Pasteuning et al. (2022), VecTabs®: Targeting misfolded and aggregated proteins with vectorized antibodies for the treatment of ALS and HD

• ASGCT poster – Duarte, et al (2025) Targeting misfolded mutant HTT protein with vectorized antibodies for the treatment of Huntington Disease

Platform technology

• ESGCT Poster - Spits et al. (2022), Gene Therapy Mediated Targeted Protein Degradation in Neurodegenerative Disease Models

• ESGCT poster - Gallego et al. (2022), Next generation rAAV capsids show enhanced transduction efficiency in 2D and 3D human cellular models for neurodegenerative diseases

• ASGCT poster – Puri et al (2025) An Optimized Baculovirus Generation Process and Novel ITR-Transgene Design for High Quality AAV Production Using the Insect Cell Production Platform